```html

Obesity (Class II) – Comprehensive Medical Guide

Overview

Obesity is a chronic, multifactorial disease characterized by excess body fat that impairs health. The World Health Organization (WHO) classifies obesity into three classes based on body‑mass index (BMI):

• Class I: BMI 30.0–34.9 kg/m²
• Class II: BMI 35.0–39.9 kg/m²
• Class III (severe or morbid obesity): BMI ≥ 40 kg/m²

Class II obesity therefore refers to individuals whose BMI falls between 35 and 39.9 kg/m². This level of excess weight markedly raises the risk of cardiovascular disease, type 2 diabetes, certain cancers, and reduced quality of life.

Who it affects: In the United States, about 9 % of adults (≈ 28 million people) have Class II or higher obesity, with higher prevalence among middle‑aged (45–64 years) women, non‑Hispanic Black and Hispanic populations, and individuals living in socio‑economically disadvantaged neighborhoods.<sup>[1] CDC, 2023</sup>

Global prevalence: Worldwide, the prevalence of Class II obesity has more than doubled in the last three decades, now affecting roughly 4 % of adults in high‑income nations and an increasing share in low‑ and middle‑income countries.<sup>[2] WHO, 2022</sup>

Symptoms

Obesity itself is a diagnosis based on BMI or body‑fat measurements, but many patients experience a constellation of signs and symptoms caused by excess adipose tissue and its metabolic effects.

Physical symptoms

• Excess body weight – visibly larger abdomen, hips, thighs, or neck.
• Reduced mobility – difficulty climbing stairs, walking long distances, or performing everyday tasks.
• Breathlessness – especially on exertion, due to increased work of breathing and possible obstructive sleep apnea.
• Joint pain – especially in knees, hips, and lower back from added mechanical load.
• Skin changes – including intertrigo (irritation in skin folds), striae (stretch marks), and acanthosis nigricans (dark, velvety patches).
• Fatigue – chronic low‑energy levels not explained by other conditions.

Metabolic and systemic symptoms

• Increased thirst & urination – early sign of insulin resistance or diabetes.
• Elevated blood pressure – often measured during routine check‑ups.
• Elevated fasting glucose or A1C – indicating pre‑diabetes or type 2 diabetes.
• Elevated cholesterol/triglycerides – dyslipidemia common in Class II obesity.
• Snoring or witnessed pauses in breathing – hallmark of obstructive sleep apnea.
• Psychological symptoms – low self‑esteem, depression, anxiety, or binge‑eating behaviors.

Causes and Risk Factors

Obesity results from an energy imbalance—more calories consumed than expended—interacting with genetics, environment, and behavior.

Primary contributors

1. Genetics: Over 300 genetic loci are linked to BMI. Certain rare syndromes (e.g., Prader‑Willi) dramatically increase risk.
2. Environment: Easy access to calorie‑dense, nutrient‑poor foods and sedentary lifestyles (e.g., screen time, automobile dependence).
3. Behavioral factors: Chronic overeating, frequent consumption of sugar‑sweetened beverages, irregular meal patterns, and low physical activity.
4. Endocrine & metabolic disorders: Hypothyroidism, Cushing’s syndrome, polycystic ovary syndrome, and certain medications (e.g., glucocorticoids, atypical antipsychotics).
5. Psychosocial stress: Emotional eating, sleep deprivation, and chronic stress raise cortisol, promoting visceral fat accumulation.

Who is at higher risk?

• Adults with a family history of obesity or type 2 diabetes.
• Individuals living in “food deserts” without affordable fresh produce.
• Those with low socioeconomic status, limited health literacy, or limited access to safe recreation spaces.
• People who have previously experienced weight‑gain‑promoting medications.
• Certain ethnic groups (e.g., African‑American, Hispanic, Native American) who develop metabolic complications at lower BMIs.

Diagnosis

Diagnosis is primarily anthropometric, supplemented by laboratory and imaging studies to assess complications.

Anthropometric measures

• Body‑Mass Index (BMI): Weight (kg) ÷ height (m)². Class II obesity = 35.0–39.9 kg/m².
• Waist circumference: > 102 cm (40 in) in men or > 88 cm (35 in) in women signals excess visceral fat.
• Waist‑to‑height ratio: > 0.5 is associated with higher cardiometabolic risk.

Laboratory tests

• Fasting glucose or HbA1c – screen for diabetes.
• Lipid panel – assess dyslipidemia.
• Liver enzymes (ALT, AST) – evaluate non‑alcoholic fatty liver disease (NAFLD).
• Thyroid‑stimulating hormone (TSH) – rule out hypothyroidism.

Imaging & other assessments (when indicated)

• Abdominal ultrasound or FibroScan – assess liver fat and fibrosis.
• Polysomnography – diagnose obstructive sleep apnea.
• Cardiovascular risk calculators (e.g., ASCVD risk estimator) – guide treatment intensity.

Treatment Options

Treatment is multimodal, aimed at sustainable weight loss (5‑15 % of initial weight) and reduction of comorbidities.

Lifestyle Modification (First‑line)

1. Medical Nutrition Therapy – a calorie‑deficit diet (500–750 kcal/day less than maintenance) individualized by a registered dietitian. Emphasis on whole foods, high fiber, lean protein, and limited added sugars.
2. Physical Activity – at least 150 minutes/week of moderate‑intensity aerobic activity plus two days of resistance training. Gradual progression is key for joint‑friendly options (e.g., swimming, stationary cycling).
3. Behavioral Counseling – cognitive‑behavioral therapy, motivational interviewing, or structured programs such as the Diabetes Prevention Program (DPP).

Pharmacotherapy

Guidelines (AACE, 2022) recommend considering medication when BMI ≥ 35 kg/m² or ≥ 30 kg/m² with obesity‑related comorbidities, after lifestyle attempts have failed for ≥ 3 months.

Medication (US)	Mechanism	Typical Use	Common Side Effects
Orlistat	Lipase inhibitor – blocks absorption of ~30 % of dietary fat	Adjunct to diet; FDA‑approved for BMI ≥ 30	Steatorrhea, fat‑soluble vitamin deficiency
Phentermine‑Topiramate (Qsymia)	Appetite suppression + increased satiety	BMI ≥ 30 with ≥ 1 comorbidity or ≥ 35	Dry mouth, insomnia, paresthesia, teratogenic
Lorcaserin (withdrawn)	5‑HT2C agonist	—	—
Naltrexone‑Bupropion (Contrave)	Opioid antagonist + dopaminergic‑noradrenergic stimulant	BMI ≥ 30 with comorbidity	Nausea, headache, increased BP
Liraglutide 3.0 mg (Saxenda)	GLP‑1 receptor agonist – slows gastric emptying, increases satiety	BMI ≥ 30 or ≥ 27 with comorbidity	GI upset, pancreatitis risk
Semaglutide 2.4 mg (Wegovy)	Long‑acting GLP‑1 agonist	Approved for Class II obesity; > 15 % weight loss in trials	GI symptoms, gallbladder disease

Procedural Interventions

• Bariatric surgery – recommended for BMI ≥ 40, or ≥ 35 with uncontrolled comorbidities when lifestyle/pharmacotherapy fails. Common procedures:
  • Roux‑en‑Y gastric bypass (RYGB)
  • Vertical sleeve gastrectomy (VSG)
  • Laparoscopic adjustable gastric band (less common now)
  Weight loss of 25‑35 % of initial weight is typical, with durable improvement in diabetes, hypertension, and sleep apnea.<sup>[3] NIH, 2023</sup>
• Endoscopic therapies – intragastric balloons, endoscopic sleeve gastroplasty—less invasive but modest weight loss (10‑15 %).

Adjunctive Therapies

Addressing sleep apnea (CPAP), treating depression/anxiety, and reviewing medication regimens for weight‑gain side effects are essential components of a comprehensive plan.

Living with Obesity (Class II)

Successful long‑term management hinges on everyday habits and support systems.

Practical daily tips

1. Meal planning: Prepare balanced meals ahead of time; use portion-control containers.
2. Mindful eating: Eat without distractions, chew slowly, pause between bites.
3. Hydration: Aim for 2–3 L of water daily; replace sugary drinks with water or unsweetened tea.
4. Movement breaks: Stand or walk for 5 minutes every hour; use a step‑counter goal of ≥ 7,000 steps/day.
5. Sleep hygiene: 7–9 hours/night; limit screens before bed; maintain a consistent schedule.
6. Stress management: Deep‑breathing, yoga, or short walks can curb stress‑related overeating.
7. Support network: Join a weight‑loss support group, involve family in healthy cooking, or use a health‑coach app.
8. Regular monitoring: Track weight weekly, waist circumference monthly, and schedule labs every 6–12 months.

Technology aids

• Apps that log food (MyFitnessPal, Lose It!) and activity (Fitbit, Apple Watch).
• Tele‑health visits for dietitian or behavioral counseling.
• Online communities (e.g., r/loseit, r/ObesityHelp) for peer motivation.

Prevention

Primary prevention focuses on creating environments that make healthy choices easier.

• Nutrition education in schools – teaching children portion size, reading labels, and cooking skills.
• Policies limiting sugary‑drink sales in schools and public venues.
• Urban planning – safe sidewalks, bike lanes, and parks to encourage active transport.
• Workplace wellness programs – standing desks, scheduled movement breaks, healthy cafeteria options.
• Screening & early intervention – routine BMI checks at primary‑care visits, with referral to dietitian at BMI ≥ 30.

Complications

If untreated, Class II obesity dramatically raises the risk of multiple organ system diseases.

Cardiometabolic

• Hypertension – risk roughly 3‑fold higher.
• Type 2 diabetes – prevalence up to 30 % in Class II versus 5 % in normal‑weight adults.<sup>[4] Mayo Clinic, 2022</sup>
• Atherosclerotic cardiovascular disease – increased MI and stroke rates.
• Non‑alcoholic fatty liver disease (NAFLD) progressing to steatohepatitis, cirrhosis.

Respiratory

• Obstructive sleep apnea – affects > 60 % of individuals with BMI > 35.
• Obesity‑hypoventilation syndrome.

Musculoskeletal

• Osteoarthritis of knees, hips, and lumbar spine.
• Reduced mobility leading to falls.

Oncologic

Higher incidence of endometrial, breast (post‑menopausal), colon, kidney, and pancreatic cancers.<sup>[5] WHO, 2021</sup>

Psychiatric and social

• Depression, anxiety, binge‑eating disorder.
• Weight bias in health care, employment, and education.

When to Seek Emergency Care

---

Sources:

1. Centers for Disease Control and Prevention. Adult Obesity Prevalence. 2023.
2. World Health Organization. Obesity and Overweight. 2022.
3. National Institute of Diabetes and Digestive and Kidney Diseases. Bariatric Surgery. 2023.
4. Mayo Clinic. Obesity. 2022.
5. World Health Organization. Cancer Fact Sheet. 2021.

```